Cannabinoid receptors as therapeutic objectives for metabolic diseases and obesity.

Among the most important pharmacological objectives proposed in the past 10 years for fighting obesity and related metabolic disorders is the endocannabinoid system (ECS). The role of the endocannabinoid system (ECS) is crucial in regulating the rewarding properties of food, in controlling energy balance by acting at the hypothalamic circuitries involved in food intake, and in peripheral metabolism by influencing hepatocytes, adipocytes, pancreatic endocrine cells, and myocytes. Obesity appears to be a condition correlated with a pathological overactivation of the endocannabinoid system (ECS); therefore, restoring a normal endocannabinoid tone by antagonizing the cannabinoid receptor type 1 (CB1) could help arrest both the maintenance and the development of obesity.

Be the first to comment

Leave a Reply

Your email address will not be published.